Draft Guidance on Indapamide

Contains Nonbinding Recommendations

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient:  Indapamide

Dosage Form; Route:  Tablet; oral

Recommended Studies:  Two studies

1. Type of study:  Fasting
   Design:  Single-dose, two-treatment, two-period crossover in vivo
   Strength:  2.5 mg
   Subjects:  Males and non-pregnant, non-lactating females, general population
   Additional comments:  None

2. Type of study:  Fed
   Design:  Single-dose, two-treatment, two-period crossover in vivo
   Strength:  2.5 mg
   Subjects:  Males and non-pregnant, non-lactating females, general population
   Additional comments:  None

Analyte to measure (in appropriate biological fluid):  Indapamide in whole blood

Bioequivalence based on (90% CI):  Indapamide

Waiver request of in vivo testing:  1.25 mg may be considered for a waiver of in vivo bioequivalence testing based on (i) acceptable bioequivalence studies on the 2.5 mg strength, (ii) proportionally similar across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths

Dissolution test method and sampling times:  The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application.

Recommended Jul 2008; Revised Nov 2019